MALFORMATIONS OF THE CENTRAL NERVOUS SYSTEM INDUCED BY NEUROTROPIC DRUGS IN MOUSE EMBRYOS

A Jurand1

  • 1University of Edinburgh, Institute of Animal Genetics, West Mains Road, Edinburgh EH 9 3JN, United Kingdom.

Insights

Twelve of fifteen neurotropic drugs caused central nervous system malformations in mouse embryos. These neurotropic teratogens, when given during neural tube closure, induced a recurring syndrome of birth defects.

Area of Science:

  • Developmental toxicology
  • Neuroscience
  • Pharmacology

Background:

  • Neurotropic drugs, including antidepressants, antipsychotics, and analgesics, are widely used.
  • The potential for these drugs to affect embryonic development, particularly the central nervous system (CNS), is a critical concern.

Purpose of the Study:

  • To investigate the teratogenic potential of various neurotropic drugs on the developing CNS in mouse embryos.
  • To characterize the specific malformations induced by these drugs and explore potential correlations with drug properties.

Main Methods:

  • A sample of fifteen neurotropic drugs (antidepressants, antipsychotics, antianxiety, anticonvulsant, opiates, synthetic analgesics) was administered to pregnant mice at the beginning of the ninth day of gestation.
  • Embryos (13 days old) were examined for CNS malformations.

Main Results:

  • Twelve out of fifteen tested neurotropic drugs were found to be teratogenic, causing significant CNS malformations in mouse embryos.
  • A recurring syndrome of malformations was observed, including exencephaly, myeloschisis, hydrocephalus, spinal cord kinking, and hydromyelia.
  • Some drugs also induced branchyury or anury, with or without lumbar myeloaplasia.

Conclusions:

  • Neurotropic drugs possess teratogenic potential for the embryonic CNS, especially when administered during neural tube closure.
  • The specific pattern and location of malformations may be influenced by the pharmacological properties of the neurotropic agents.
  • Further research is needed to confirm these provisional findings and elucidate drug-specific teratogenic mechanisms.